Closing the Evidence Gap in Cardiopulmonary Mobility
TICM is the translational institute within Texas Pulmonary Foundation, building clinical protocols, pilot frameworks, and decision-useful evidence for cardiopulmonary mobility technologies.
Texas Pulmonary Foundation
Research initiative • 501(c)(3) nonprofit
Closing the Evidence Gap in Cardiopulmonary Mobility
TICM is the translational institute within Texas Pulmonary Foundation, building clinical protocols, pilot frameworks, and decision-useful evidence for cardiopulmonary mobility technologies. The work is designed for regulatory, payer, and adoption decisions, not just publication.
What brings you here?
TICM works across three distinct roles. Find yours below.
Device or Technology Company
Validate your technology with clinical populations and endpoints that reach regulatory, payer, and adoption decisions.
Clinical or Academic Researcher
Join a translational research platform designed to generate evidence that reaches practice, not just publication.
Philanthropic Supporter
Enable the evidence infrastructure that lets promising technologies reach the patients who need them.
Good Technology Stalls at the Evidence Gap
The barrier to clinical adoption is rarely the device. It is the evidence. Generated too slowly, sized for publication rather than regulatory decisions, and fragmented across studies that do not build on each other.
Enrollment bottlenecks
Relevant patient populations are unreachable through standard trial networks.
Misaligned endpoints
Data that earns a publication but cannot support a coverage decision or regulatory submission.
Fragmented evidence
Disconnected studies that produce volume without coherence. No study sets up the next.
Slow site activation
Months of institutional overhead before the first patient is enrolled.
A New Clinical Variable Requires a New Protocol Logic
Adjustable assistance changes the physiologic demand of walking, creating a progression variable that traditional rehabilitation evidence models were not built to handle. TICM exists to make that variable clinically usable and measurable.
Designed around the bottleneck
Every structural decision at TICM reflects one goal: generate evidence that actually moves a technology toward clinical adoption.
01
Clinical Access
Operating within active cardiopulmonary and rehabilitation settings, reaching the populations standard trial networks miss.
02
Lean Study Design
Studies sized to where a technology actually is, generating evidence for the next decision rather than the largest defensible trial.
03
Decision-Grade Endpoints
Outcomes selected to persuade across peer review, regulatory submission, and payer evaluation in a single study.
Where the evidence gap is widest
Three domains defined by the distance between technological capability and available clinical evidence.
Wearable Robotics & Assisted Mobility
Functional and cardiopulmonary outcomes for exoskeletons and powered mobility devices.
Cardiopulmonary Performance & Functional Recovery
Exercise capacity, respiratory performance, and return to daily activity.
Real-World Physiologic Validation
Validating sensor-derived metrics against clinically meaningful outcomes in naturalistic settings.
Clinician-led. Embedded in practice.
Study design stays grounded in clinical realities because TICM operates inside them, not alongside them.
Clinical Research Home
Breathing Center of Houston
High-volume cardiopulmonary care | Houston, TX
If the evidence is the barrier,
this is where to start.
Cardiopulmonary mobility is one of the most consequential and least-evidenced areas in rehabilitation and assistive technology. TICM was built for this conversation.